ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Maren Kühr contributed 232 entries already.
Biomanufacturing promises domestic, sustainable, sovereign and resilient production. Capacities are trapped in outdated scale-up processes. SPRIND urges investment and disruptive innovation to propel biomanufacturing. Demands are decentralised, non-sterile & continuous biomanufacturing capabilities.
Spain’s biotech sector drives innovation, economic growth, and scientific excellence. With strong R&D investment, global research impact, and a leading role in gender equality, it’s a key player in health, sustainability, and strategic autonomy. BIOSPAIN 2025 in Barcelona will showcase its potential and connect global biotech leaders.
The CEO of Lund-based Enzymatica AB, Claus Egstrand, is stepping down from his role. CFO Therese Filmersson will also leave her position. The process of finding their successors has already begun.
Pichia pastoris (syn. Komagataella phaffii), a methylotrophic yeast, is a proven platform for pharmaceutical protein production. However, its potential reaches far beyond. As a reliable, scalable, and cost-efficient platform for recombinant protein expression, Pichia is equally suited for industrial enzymes, food & feed, diagnostics, and biomaterials.
Iions.bio was founded in 2024 and is located in the Innovation and Startup Centre IZB in Planegg-Martinsried.
In today’s rapidly evolving world, adapting to demand volatilities while ensuring uninterrupted supply of biological medicines is more critical than ever. At Boehringer Ingelheim, our global biopharmaceutical network delivers flexibility, resilience, and reliability. By leveraging harmonised procedures, standardised setups, and innovative logistics, we ensure the biologics we produce reach those in need – even during unexpected challenges.
In addition to the uncertainty triggered by the US government with serious changes at the FDA and other healthcare institutions and an unclear stance of the US Secretary of Health and Human Services on various areas of innovation, the growing demand for health care services gives a positive momentum that can provide stability.
In the life sciences industry, Quality Management (QM) has long been synonymous with compliance: checking boxes to meet regulatory demands. But that definition no longer holds up. Today, QM must do much more than ensure compliance; it needs to enable speed, scalability, and sustained innovation across complex, global operations. To do that, prominent gaps need to be filled.
It all began with a view from the window of the 15th floor of Bayer’s site in Berlin, reminiscent of Boston before it became one of the most important biotech hotspots in the world. This inspired the vision of developing the Bayer Campus into “Boston an der Spree” – a vibrant healthcare campus that fosters collaboration and innovation.
In life sciences, breakthroughs are reshaping healthcare faster than ever. But true leadership means going beyond the lab – understanding the complex ecosystem where science, policy, and business collide. For those struggling to navigate this complexity, WU Vienna’s Executive MBA offers the insights and connections needed to stay ahead in an unpredictable industry.